Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...

AbbVie (NYSE: ABBV) today announced that nine provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

Micrograph of a diffuse large B cell lymphoma, AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer partnership, with bispecific antibody Epkinly now cleared ...

Company History AbbVie, founded in 2013, produces several immune modulators such as Skyrizi and Humira, drugs widely used for the treatment of diseases such as psoriasis, rheumatoid arthritis, and ...

Genmab GMAB over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes ...

Narus Financial Partners LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 8.4% in the 3rd quarter, ...

AbbVie (NYSE:ABBV – Free Report) had its target price upped by BMO Capital Markets from $214.00 to $220.00 in a research note ...

AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

The U.S. Food and Drug Administration (FDA) has approved the fourth indication for AbbVie's (NYSE:ABBV) anti-wrinkle therapy Botox Cosmetic, expanding its use beyond the face for the first time ...

About AbbVie Inc and Novo Nordisk A/S (ADR ... Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat ...

AbbVie Inc. discovers, develops ... Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers ...